ORPHA:247203
Collecting duct carcinoma
Also known as: BDC · Bellini carcinoma · Bellini duct carcinoma · CDC
Publications
1,993
Trials
11
Interventional, condition-specific
Researchers
1,338
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Collecting duct carcinoma is a rare, aggressive subtype of renal cell carcinoma, which originates from the epithelium of the distal collecting ducts, and usually manifests with hematuria, flank pain, palpable abdominal mass or nonspecific symptoms, such as fatigue, weight loss or fever. Patients are often asymptomatic for long periods of time and therefore, disease is often locally advanced or metastatic at the time of diagnosis. In cases with metastatic spread, bone pain, cough, dyspnea, pneumonia or neurological compromise may be associated.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0005220
- UMLS:C1266044
- NCIT:C6194
Additional Mondo synonyms (15)
cDC · carcinoma of collecting duct of renal tubule · carcinoma of collecting ducts of Bellini · carcinoma of kidney collecting duct · carcinoma of renal collecting duct · carcinoma of the collecting ducts of Bellini · carcinoma of the kidney collecting duct · carcinoma of the renal collecting duct · collecting duct carcinoma · collecting duct of renal tubule carcinoma · collecting duct renal cancer · collecting duct renal cell carcinoma · kidney collecting duct carcinoma · renal carcinoma, collecting duct type · renal collecting duct carcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,993 matched papers (1,095 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
11 matched on ClinicalTrials.gov (3 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
1,993
1,993 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
1,993 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
1,095 in the last 10 years · low confidence
Phrase hits: 1,993 · MeSH hits: 0
Who's working on it?
1,338
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Liu Y9 papers · 2026
Department of Gastrointestinal Surgery, Peking University First Hospital, Peking University, Beijing, China.
Papers in Europe PMC - 02Wang H8 papers · 2025
Department of Urology; Department of Pathology, Temple University Hospital, 3401 N, Broad Street, Philadelphia, PA 19147, USA.
Papers in Europe PMC - 03Xu H6 papers · 2026
Department of Pathology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Papers in Europe PMC - 04Yang X6 papers · 2026
Department of Pathology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: yxq11964@rjh.com.cn.
Papers in Europe PMC - 05Zhou L6 papers · 2026
Department of Pathology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: zhouluting@163.com.
Papers in Europe PMC - 06Chen J5 papers · 2026
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Papers in Europe PMC - 07Li Y5 papers · 2025
Nephrology Department of Chongqing Hospital of Traditional Chinese Medicine, China.
Papers in Europe PMC - 08Procopio G5 papers · 2026
Genitourinary Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Papers in Europe PMC - 09Verzoni E5 papers · 2026
Genitourinary Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Papers in Europe PMC - 10Wang C5 papers · 2026
Department of Pathology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: wangchaofu@126.com.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
11
interventional trials for this specific condition
11 interventional trials matched this specific condition name; 3 currently recruiting in our sample.
Data as of 27 July 2026
11 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 92.1th percentile).
low confidence · 92.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
11 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT03866382·RECRUITING·Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Conditions: Bladder Adenocarcinoma · Bladder Clear Cell Adenocarcinoma · Bladder Mixed Adenocarcinoma · Bladder Neuroendocrine Carcinoma·Matched via name phrase
- NCT06211114·RECRUITING·Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
Conditions: Collecting Duct Carcinoma·Matched via name phrase
- NCT06302569·RECRUITING·Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma
Conditions: Bellini Carcinoma · Collecting Duct Carcinoma · Renal Medullary Carcinoma·Matched via name phrase
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Collecting duct carcinoma" OR "Bellini carcinoma" OR "Bellini duct carcinoma" OR "carcinoma of collecting duct of renal tubule" OR "carcinoma of the collecting duct of the renal tubule" OR "carcinoma of collecting ducts of Bellini" OR "carcinoma of the collecting ducts of the Bellini" OR "carcinoma of kidney collecting duct" OR "carcinoma of the kidney collecting duct" OR "carcinoma of renal collecting duct" OR "carcinoma of the renal collecting duct" OR "carcinoma of the collecting ducts of Bellini" OR "collecting duct of renal tubule carcinoma" OR "collecting duct of the renal tubule carcinoma" OR "collecting duct renal cancer" OR "collecting duct renal cell carcinoma" OR "kidney collecting duct carcinoma" OR "renal carcinoma, collecting duct type" OR "renal collecting duct carcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Collecting duct carcinoma" OR "Bellini carcinoma" OR "Bellini duct carcinoma" OR "carcinoma of collecting duct of renal tubule" OR "carcinoma of the collecting duct of the renal tubule" OR "carcinoma of collecting ducts of Bellini" OR "carcinoma of the collecting ducts of the Bellini" OR "carcinoma of kidney collecting duct" OR "carcinoma of the kidney collecting duct" OR "carcinoma of renal collecting duct" OR "carcinoma of the renal collecting duct" OR "carcinoma of the collecting ducts of Bellini" OR "collecting duct of renal tubule carcinoma" OR "collecting duct of the renal tubule carcinoma" OR "collecting duct renal cancer" OR "collecting duct renal cell carcinoma" OR "kidney collecting duct carcinoma" OR "renal carcinoma, collecting duct type" OR "renal collecting duct carcinoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 11 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: BDC; CDC
Confidence reasoning
- Preferred label is multi-word and distinctive
- 2 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (1993) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T10:30:12.315Z
